Organon logo

Organon

OGN | NYSE
Chart Builder DCF Calculator
$13.90
$0.00 (0.00%)
At close: Nov 16, 2026, 4:00 PM ET
$13.90
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:00 PM ET
+0.00%

Rating

Updated: Nov 16, 2026
38.5
Fundamentals Weak
Market Sentiment Bullish
Moat Narrow
Sector Rank #568/1021 (Top 56%)

Key Statistics

Market Data

Market Cap $3.65B
1D Range
13.88 13.91
52W Range
5.70 13.91

Valuation (TTM)

PE 18.29
PB 3.06
EV/EBITDA 8.31

Valuation (NTM)

Forward PE 4.15
Forward PEG -1.64
Price Target $12.00
Loading financial charts...

Profile

Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, en...

Sector Healthcare
Employees 10,000
IPO Date May 14, 2021
Fiscal Year January - December

Latest News

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

6 days ago · zacks.com

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Organon (OGN) Q3 Earnings and Revenues Top Estimates

18 days ago · zacks.com

Organon (OGN) Q3 Earnings and Revenues Top Estimates
Organon Announces Quarterly Dividend

18 days ago · businesswire.com

Organon Announces Quarterly Dividend
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

22 days ago · zacks.com

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

29 days ago · businesswire.com

Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

1 month ago · businesswire.com

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

1 month ago · zacks.com

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

2 months ago · zacks.com

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

2 months ago · businesswire.com

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

2 months ago · zacks.com

Is Trending Stock Organon & Co. (OGN) a Buy Now?

Earnings

Latest Earnings
Oct 30, 2026
EPS
$0.94
Beat +6.82%
REV
$1.57B
Miss -0.11%
Next Earnings
Feb 11, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
3
Consensus
Hold
Price Target
$12.00
Downside
-13.67%
Buy (0)
Hold (2)
Sell (1)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.